Pacific Heights Asset Management LLC Purchases Shares of 460,000 Structure Therapeutics Inc. Sponsored ADR $GPCR

Pacific Heights Asset Management LLC purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 460,000 shares of the company’s stock, valued at approximately $9,540,000.

Other large investors also recently bought and sold shares of the company. National Bank of Canada FI lifted its holdings in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after acquiring an additional 2,766 shares during the period. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after acquiring an additional 3,213 shares during the period. Signaturefd LLC lifted its holdings in Structure Therapeutics by 6,550.0% in the second quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock valued at $138,000 after acquiring an additional 6,550 shares during the period. Parallel Advisors LLC acquired a new position in Structure Therapeutics in the second quarter valued at approximately $171,000. Finally, GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after acquiring an additional 7,627 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $26.92 on Wednesday. The business has a fifty day moving average price of $23.36 and a 200 day moving average price of $21.78. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $42.57. The company has a market cap of $1.55 billion, a P/E ratio of -25.64 and a beta of -1.65.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

GPCR has been the subject of a number of analyst reports. HC Wainwright decreased their price target on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Zacks Research downgraded Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Finally, JMP Securities reduced their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $68.67.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.